BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
BioCryst Pharma (BCRX) PT Raised to $21 at Piper Sandler, 'we continue to recommend shares'
November 4, 2024 2:20 PM ESTPiper Sandler analyst Tyler Van Buren raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $21.00 (from $20.00) while maintaining a Overweight rating.
The analyst comments "Remain OW rated on BCRX shares after this mornings Q324 Orladeyo beat and narrowed FY24 Orladeyo revenue... More
BofA Securities on BioCryst Pharma (BCRX) 'Stock’s weakness offers particularly attractive entry point'
November 4, 2024 2:06 PM EST(Updated - November 4, 2024 2:16 PM EST)
BofA Securities analyst Tazeem Ahmad reiterated a Buy rating and $11.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "BCRX reported $116.3mn in 3Q Orladeyo sales, slightly ahead of our $113.7mn and consensus $112.6mn. Mgmt highlights strong patient demand, noting US start forms were up 14.2% over the past 12 months and the paid drug rate improved to 74.8% (2Q: 74.4%). Additionally, 67 new US prescribers were added in 3Q, which is the highest add in the past eight quarters. The company narrowed FY24 Orladeyo sales guidance to... More
